Skip to content

Quantitative Myocardial Blush assessment for Coronary Microvascular Disease

Quantitative Myocardial Blush assessment for Coronary Microvascular Disease - n/a

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48332
Enrollment
15
Registered
2019-08-07
Start date
2019-08-07
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Age >18 years. * Presence of an epicardial stenosis of *50% diameter stenosis in the left anterior descending (LAD) artery. * Presence of stable angina (Canadian Cardiovascular Society (CCS) score I-III). Able to understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: Patients 13mm septal wall thickness). * Unable to undergo percutaneous intervention or receive adenosine (severe reactive airway disease, severe hypotension or high-grade Atrio-Ventricular (AV) block in the absence of a pacemaker. * Signs or history of cardiomyopathy. * Signs of (peri)myocarditis * Collateral formation in target vessel. * CABG to target vessel. * Renal failure (MDRD calculated eGFR of

Design outcomes

Primary

MeasureTime frame
Correlation of cDSA-derived parameters and Doppler flow velocity-derived parameters of microvascular resistance during hyperemic flow and coronary flow reserve, pre-and post PCI. Patiënts will receive a PCI of the LAD following standard of care. However, before the PCI 2 additional angiograms will be acquired, before and after administration of adenosine. Simultaneously, intracoronary flow and pressure will be measured with a Combowire positioned in the LAD. Following the PCI the same will be repeated.

Secondary

MeasureTime frame
Not applicable.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)